YESAFILI Q Code: Q5155

Drug & Product Overview

HCPCS Descriptor Injection, aflibercept-jbvf (yesafili), biosimilar, 1 mg

HCPCS Added Date October 1, 2025

Manufacturer Biocon Biologics Inc

Route of Administration Intravitreal

Generic Status Single-Source; Branded

Dosage Form Injection, Solution

About YESAFILI

Yesafili is a medication aligned to the HCPCS Q Code: Q5155 for billing, pricing, and reimbursement purposes in the United States. Classified under Ophthalmology, it is administered via the intravitreal route and manufactured by Biocon Biologics Inc.

Manufacturers, reach out to us to add more information.

NDC Code Information

1 NDC package is crosswalked to Q5155. Package detail is available to logged-in subscribers.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
•••••-••••-•• Log in to view	YESAFILI

Login to view 1 NDC package View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

YESAFILI Pricing & Reimbursement

Q5155 Private Payer Reimbursement

$47.30 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Aflibercept Biosimilar Information:

YESAFILI Approval Date: May 20, 2024

Product Name	HCPCS Code	Active Ingredient	BLA Type
Eylea	J0178	Aflibercept	351(a) Originator Product
Opuviz	Q5153	Aflibercept	351(k) Interchangeable
Yesafili	Q5155	Aflibercept	351(k) Interchangeable
Ahzantive	Q5150	Aflibercept	351(k) Biosimilar
Enzeevu	Q5149	Aflibercept	351(k) Biosimilar
Pavblu	Q5147	Aflibercept	351(k) Biosimilar
Eydenzelt	Q5170	Aflibercept	351(k) Biosimilar

YESAFILI CPT Administration Codes

CPT Code	Description
67028	Intravitreal injection of a pharmacologic agent (separate procedure) 67028

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

YESAFILI Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Macular Edema Following Retinal Vein Occlusion (RVO) Neovascular (Wet) Age-Related Macular Degeneration (AMD)

Drug Class

Vascular Endothelial Growth Factor Inhibitor [EPC]Vascular Endothelial Growth Factor Inhibitors [MoA]

Frequently Asked Questions

Is there an available Yesafili billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for YESAFILI.

Are there any available Yesafili patient assistance programs?

YESAFILI patient assistance information can be found through Biocon Biologics. Visit Here →

Where can I find Yesafili prescribing information?

Yesafili prescribing information can be found through the link below. Visit Here →

Where can I find Yesafili side effect information?

Yesafili side effect information can be found at the link below. Visit Here →

Does billing Yesafili require wastage modifiers?

CMS does not include YESAFILI (Q5155) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q5155. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.